Systemic sclerosis (SSc) is a heterogeneous autoimmune disease characterised by predominant T-cell activation, production of auto-Abs and cytokine release. 1 Currently, no therapies have been proven to be effective in modifying the course of SSc. Oral CY has shown a marginal benefit in skin score and pulmonary function in a randomised trial. 2 There is an urgency for more effective treatment strategies for this disease as patients with the more severe forms of the disease have a significantly reduced lifespan compared with the general population. 3, 4 Autologous haematopoietic SCT (HSCT) has been suggested as a possible treatment modality in autoimmune diseases over the past 10 years. A consensus statement outlining areas for future research was released by the European Bone Marrow Transplant (EBMT) society and European League against Rheumatism (EULAR) in 1997. 5 Since that publication, over 175 patients have undergone autologous transplant for SSc with encouraging results. 6 The eagerly awaited results of phase III ASTIS and SCOT trials will provide more definitive data on the role of HSCT in this disease. 7 Thus far, however, there have been heterogeneous patient groups in the initial phase II trials of HSCT in SSc. Previous studies have had few patients who have had pulse i.v. CY therapy before their autograft. 8 As a result, the effect of HSCT on patients who have failed pulse CY therapy remains unknown. In this study, we present our experience of HSCT in 10 heavily pre-treated patients who had failed monthly i.v. CY.
Patients aged 18-65 years were eligible for this pilot study if they had rapidly progressive inflammatory diffuse scleroderma, within 3 years of onset, involving lungs and/or heart (myocarditis) that failed to stabilise with monthly i.v. CY (that is, no change in baseline skin score) and other antirheumatic agents. A total of 10 patients (8 female, 2 male) with a median age of 43 years (range: 23-46) were transplanted between October 2002 and November 2009 at St Vincent's Hospital, Sydney, Australia. Baseline characteristics of patients are outlined in Table 1 . All patients were antinuclear Ab-positive and six had pulmonary fibrosis. All patients had failed to stabilise with i.v. CY with a median dose of 3.75 g/m 2 (1.5-6.5) with a minimum of two doses. After informed consent, a median of 7.37 Â 10 6 /kg (range: 2.14-77.2) CD34 þ stem cells were collected after CY 2 g/m 2 and G-CSF 10 mg/kg/day. Conditioning was with CY 200 mg/kg and equine antithymocyte globulin (Pfizer, Sydney, New South Wales, Australia). After the first patient developed a hypertensive crisis, all subsequent patients received captopril to a maximally tolerated dose to maintain systolic blood pressure of 100. Following engraftment, all patients received standard antimicrobial prophylaxis. There was no TRM at D100 or 1 year post HSCT. At a median follow-up of 33 months (range: 12-84), there was a significant (Po0.05) reduction in skin scores (performed by an independent dermatologist) at 3, 6, 12, 24, 36, 48, 60, 72 and 84 months post HSCT (Figure 1) . All patients experienced a significant (Po0.05) reduction in their Health Assessment Questionnaire (HAQ) and visual analogue scale (VAS) scores (disease and pain) at 3, 6, 12, 24, 36, 48, 60, 72 and 84 months. Four patients had recurrence of disease at approximately 12 months post HSCT. Two of these patients died of progressive disease. The two other patients remain alive with HAQ and VAS scores that are lower than their pre-HSCT values. Respiratory function remained stable in all patients, with no worsening of carbon monoxide transfer corrected for alveolar volume (TLCO) or total lung capacity (TLC). Most (7/8) of the patients have returned to full-time work post HSCT.
This study demonstrates that autologous HSCT is a safe and effective strategy for patients with severe SSc even when they have failed pulse CY. It is possible that there is a dose-response effect for the immunosuppressive effect of CY and HSCT where patients receive 200 mg/kg. A previous pilot study from our institution had confirmed a dose-response relationship in HSCT for rheumatoid arthritis where more sustained responses were seen with 200 mg/kg of CY than with 100 mg/kg. 9 The recently published phase II open-label ASSIST trial also demonstrated the benefit of HSCT in SSc but importantly also confirmed, like this study, that patients who had failed CY can be salvaged by HSCT. 10 There was no TRM in this study confirming a recent EBMT study 6 showing that careful patient selection and centre experience are critical for successful outcomes in autografting for autoimmune conditions. Responses to HSCT in these patients were also sustained with a median follow-up of 33 months (including three patients at 84 months), providing some reassurance about the long-term efficacy and safety of the procedure. Longer-term studies are warranted in this area, however.
In conclusion, this study confirms that HSCT is a valuable therapeutic option in the treatment of heavily pre-treated SSc patients even when they have failed pulse CY. The results of the ASTIS and SCOT trials are eagerly awaited and may confirm whether HSCT is a superior therapy to pulse CY therapy and thus become an established treatment option for patients suffering from this devastating illness.
